Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
460.96 206.71 206.04 133.79
Total non-current assets
55.56 51.64 59.99 57.40
Total Assets
516.52 258.34 266.02 191.18
Total current liabilities
372.30 140.39 132.33 75.51
Total non-current liabilities
56.45 56.94 55.07 54.84
Total liabilities
428.75 197.33 187.40 130.35
Common Equity (Total)
87.77 61.01 78.62 60.84
Shareholders Equity (Total)
87.77 61.01 78.62 60.84
Total Debt
36.96 37.05 37.15 37.25

Show all line items

In millions of $ except per-share values · columns are period end dates